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Hyaluronic acid was first described by Meyer and Palmer (1) in mammalian
tissue and by Kendall et al (2) in group A streptococci . A number of investigators
(2-11) have attempted to show that hyaluronate is immunogenic. In general,
these studies have failed to show the immunogenicity of hyaluronate, despite the
variety of methods used for immunization, including the use of hyaluronate
conjugated to BSA as a hapten-carrier immunogen (6). These studies primarily
used immunoprecipitation and agglutination reactions to detect hyaluronate
antibodies. Recent studies (12) using more sensitive techniques have indicated
that naturally occurring antibodies to hyaluronate may be found in the sera of a
number of species of animals. Other investigators (13) have suggested that
antibodies to DNA, which occur in the sera of patients with systemic lupus
erythematosus, may crossreact with hyaluronate. We have obtained data (14)
suggesting that antibodies to hyaluronate may be present in the sera of patients
with poststreptococcal glomerulonephritis.
In this study, we report data indicating that hyaluronate is immunogenic in
rabbits . Upon immunization of rabbits with formalinized encapsulated strepto-
cocci, antibodies are produced that react specifically with hyaluronate derived
from both streptococci and from mammalian tissue. By an ELISA using a
biotinylated conjugate of hyaluronidase-digested hyaluronate as antigen, and
using a number of different inhibitors, we have determined that the immuno-
dominant site of hyaluronic acid recognized by these antisera is the carboxyl
group of a terminal glucuronic acid residue. Furthermore, hidden antigenic sites
of hyaluronate, containing terminal glucuronic acid, are exposed by mammalian
(testicular) hyaluronidase treatment.
Materials and Methods
Biochemicals.
￿
Purified mammalian hyaluronate was purchased from Miles Laboratories
(Elkhart, IN), Sigma Chemical Co. (St. Louis, MO), and Worthington Biochemical Corp.
(Freehold, NJ). Chondroitin-4-sulfate and heparin were obtained from Sigma Chemical
Co. Heparan sulfate was obtained from Miles Laboratories. N-acetylglucosamine, N-
acetylgalactosamine, and glucuronic acid (sodium salt) were obtained from Sigma Chemical
Co. Galacturonic acid and glucuronamide were obtained from Aldrich Chemical Co.,
Milwaukee, WI . Testicular hyaluronidase was obtained from Worthington Biochemical
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Corp. Type III pneumococcal polysaccharide was prepared from a stock type III strain
(A66).
PreparationofStreptococcal Hyaluronate.
￿
Group C streptococcal strain D181 was grown
in a fermenter in 60 liters of dialysate medium (15) at pH 7.5, with extra glucose. When
growth ceased, the capsular hyaluronate was released from the surface of the bacterial
cells by saturating the culture medium with chloroform . The bulk of the bacteria were
then removed by Sharples centrifugation, although the process was inefficient because of
the viscosity of the hyaluronate-containing medium. The hyaluronate was precipitated by
the addition of Cetavlon at a final concentration of 0.5%, and the precipitate was washed
repeatedly with distilled water. Resolution of the precipitate in 6 liters of 1 M CaC12
yielded an almost solid gel, and this property was retained after reprecipitation with two
volumes of alcohol and resolution in 6 liters of 0.9% NaCl. This fraction is referred to as
IA, and represented 60 g hyaluronate, as estimated by glucuronate analysis.
To render the hyaluronate manageable for further manipulation, it was partially
hydrolyzed enzymatically. Two successive treatments with testicular hyaluronidase (Wor-
thington Biochemical Corp.) were carried out at room temperature for 24 h at 20 and
100 mg/liter, respectively, using a total of 60 gm (10 gm/liter) of hyaluronate. The
solution was now markedly reduced in viscosity and was filtered with suction through a
bed of filter cel to remove residual bacteria and insoluble material. Fraction IA, was
recovered by precipitation with one volume of alcohol, and presumably represents the
larger oligosaccharide fragments remaining after enzymatic hydrolysis. This fraction
contained 4.25 g of material, which on analysis showed N-acetylglucosamine, 49.0% (16)
and glucuronic acid 47 .7% (17). Fraction IA2 was a crystalline fraction that appeared in
the supernatant fluid of fraction IA, ; 10.1 g of this fraction were obtained, which on
analysis contained 50% N-acetylglucosamine and 49.9% glucuronic acid.
Biochemical Modifications ofHyaluronate.
￿
To determine the immunodominant site of
reactivity of hyaluronic acid, two methods for the biochemical modification of IA, were
used. (a) Periodate oxidation and borohydride reduction: a modification of a previously
described method (18) was used . 20 mg IA, was dissolved in 10 ml 0.1 M sodium meta-
periodate (Sigma Chemical Co.) and rotated in the dark at room temperature for 4 h.
The reactivity was monitored at 225 nm. After 4 h, a moderate decrease in absorbance
was noted in the reaction solution compared to control solutions. The material was
dialyzed against distilled water and lyophilized. The lyophilized material (5 mg) was
dissolved in distilled water (1 mg/ml). 250 mg of sodium borohydride was slowly added
at room temperature, and the mixture was stirred for 4 h . The solution was then
neutralized with 4 N HCI, dialyzed against distilled water, and lyophilized. The final
material was labelled as IA,-periodate. (b) Carboxyl reduction: carboxylic groups of IA,
were reduced according to the method of Taylor and Conrad (19). 30 mg of IA, were
dissolved in 10 ml of distilled water. 191 .7 mg of 1-ethyl-3-(3-dimethylaminopro-
pyl)carbodiimide (EDAC) was slowly added, and the solution was titrated to pH 4 .75 with
0.1 N HCI. The solution was stirred for 2 .5 h, with the pH constantly titrated to pH 4.75.
20 ml of 2 M sodium borohydride was slowly added, with the pH maintained at 8 .0 with
4 N HCI. The reaction mixture was stirred for 30 min. Finally, the mixture was dialyzed
against distilled water and lyophilized. This material was labeled as IA,-carboxyl.
Immunization of Rabbits with Encapsulated Streptococci.
￿
Vaccines were prepared by
formaldehyde treatment of streptococci harvested in the log phase of growth in an attempt
to promote retention of the capsule. The strains used were S23op (group A, type 14) and
D181 (group C). The organisms were grown in Todd-Hewitt broth, recovered by
centrifugation and resuspended in a solution containing 1 .5% formaldehyde and 7.5%
sucrose. After refrigeration for 3 d, the cells were washed twice with phosphate buffer,
pH 7 .5, and resuspended in the buffer. Capsules were readily demonstrable by the India
ink method, although those on the S23op cells appeared much smaller than before
formaldehyde treatment. Chemical analysis for glucuronic acid in the capsular material
released from an aliquot of the vaccine by chloroform indicated the presence of 60 jug/ml
hyaluronate in the S23op preparation and 300 jug/ml in D181 . The vaccines were764
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distributed in a series of plastic tubes and stored at -80°C until use . Freezing and thawing
had no adverse effect on the capsules.
Rabbits were given a series of intravenous injections with the vaccines, two with S23op
(rabbits 4511 and 4512) and two with D181 (rabbits 4513 and 4514). 1 ml was given on
three successive days, followed by a test bleeding 1 wk later. After the fifth injection
series, the animals were challenged intravenously with a suspension of living D181
organisms. Only one (4514) survived, and two further test bleedings were obtained from
this rabbit.
Conjugation of Streptococal Hyaluronate to BSA .
￿
Intact streptococcal hyaluronate (frac-
tion IA) was conjugated to BSA (Cohn fraction V; Sigma Chemical Co.) This was done to
assure binding of the hyaluronate to the ELISA plates via the protein portion of the
conjugate. 20 mg of fraction IA were placed in 10 ml 0.1 M sodium phosphate, pH 8.0,
and briefly sonicated until solubilized. 2.5 ml of 250 mM benzoquinone (Pierce Chemical
Co., Rockford, IL) in absolute ethanol were added to the lA solution and rotated at room
temperature for 20 min. 100 ml of ethanol/sodium acetate was added, and the mixture
was centrifuged at 12,100 g for 15 min. The pellet was retained and washed twice with
ethanol/acetate. BSA was acid-inactivated to destroy associated alkaline phosphatase
activity as follows : 11 mg of BSA was added to 2 ml of distilled water, brought to pH 2.0
with 5 N HCl, and incubated for 20 min at room temperature. After incubation, the BSA
solution was brought to pH 8 .0 with 2 ml of 0.1 M sodium phosphate. Finally, the solution
of acid-inactivated BSA was added to the pellet of hyaluronate-benzoquinone and rotated
overnight at 4°C.
The conjugated material was then chromatographed on a 2.5 X 180 cm. column of
Sephacryl 5200 in 0.1 M Tris buffer, pH 8. Three peaks were obtained when the column
was analyzed by absorption at 280 nm. A plateau of absorbance was noted in fractions
34-37 and 38-40. Finally, a peak was noted in fractions 61-70. An analysis of the column
for glucuronic acid (20) revealed that the majority of glucuronic acid eluted in the
fractions from 10-45, with decreasing amounts of glucuronic acid from fraction 10 to
fraction 45, and little or no glucuronic acid in fractions beyond 55. SDS-PAGE analysis,
using a 10% gel, revealed that fractions 35-40 contained material that chromatographed
as a diffuse, high molecular mass smear, with a sharper band appearing at 68 kD, while
fractions 65-67 contained only a sharp band at 68 kD. Dot immunoblotting analysis of
the column fractions showed that the fractions containing protein all reacted with a rabbit
antiserum against BSA (Cappel Laboratories, Cochranville, PA). These data indicate that
fractions 34-37 contained a significant amount ofhigh molecular mass material containing
both glucuronic acid and protein, with the highest ratio of glucuronic acid/protein in
fractions 34-36. Fraction 35 was chosen for use as antigen in the ELISA, and is referred
to as hyaluronate-BSA. Total protein was assessed by a colorimetric assay (Pierce Chemical
Co.). The material was diluted to 10 ug/ml in Tris buffer and added to ELISA plates kept
overnight at 4°C. After washing, rabbit sera in PBS with 0.5% Brij (PBSB)' were added
for 1 h, and subsequent steps were performed as described above.
Preparation ofBiotinylated Streptococcal Hyaluronate.
￿
A second method for binding the
hyaluronate to the ELISA plates was used (21) with some modifications for the introduc-
tion of a spacer arm (22). Biotinylated hyaluronate was prepared using the fraction IA, .
25 mg of fraction IA, in 20 ml PBS was added to 5 ml of 250 mM benzoquinone (Aldrich
Chemical Co.) in 100% ethanol. The mixture was rotated for 1 h at room temperature in
the dark. 100 ml of absolute ethanol with 0.05 M sodium acetate was added, the mixture
brought to 4°C, and centrifuged at 17,700 g for 20 min. The pellet was resuspended in
100 ml of ethanol/acetate and centrifuged a second time. After this, the pellet was
resuspended in 18 ml of 0.5 M NaCl and dialyzed against 1 liter of 0.5 M NaCl at 4°C.
2.25 ml of 1 .0 M diaminodipropylamine was added to the reaction mixture, and the
mixture was rotated overnight at 4°C. The mixture was then dialyzed against 0.1 M
NaHC03 at 4°C, and centrifuged at 1,500 g to remove precipitated material. The
conjugated hyaluronate in the supernatant was tested for free amino groups (23). 25 mg
N-hydroxysuccinimide biotin (Sigma Chemical Co.) was dissolved in 5 ml of DMSO and
' Abbreviation used in this paper:
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added to 20 ml of the supernatant containing free amino groups. This mixture was
rotated overnight at 4°C and then dialyzed against distilled water and lyophilized. The
biotinylated hyaluronate (IAI-B) was tested for glucuronic acid by the carbazole reaction
(20) using d-glucuronolactone (Sigma Chemical Co.) as a standard. ^48% of the total
weight of the IA I -B was glucuronic acid, indicating that 96% of the sample was probably
hyaluronic acid, while 4% of the sample represented biotin and the linking peptides.
Group C meningococcal polysaccharide obtained as previously described (24) was bioti-
nylated in the same manner as described above.
Enzyme-linkedimmunosorbent assay.
￿
ELISA were performed essentially as we previously
described (14), with some modifications for the use of streptavidin and biotin-labelled
polysaccharides (25). ELISA plates (Immunoplate 11; Nunc, Roskilde, Denmark) were
coated with hyaluronate-BSA conjugate in various concentrations in 50 WI 0.1 M Tris
buffer (pH 9.8) with 0.3 mM MgC12 overnight at 4°C. For experiments employing
streptavidin (Sigma Chemical Co.) (10 tag/ml Tris buffer), streptavidin was first bound to
the ELISA plates overnight at 4°C, the plates were washed, and biotinylated hyaluronate
in PBSB was added for 2 h at room temperature. After this incubation, the plates were
washed in 0.9% NaCI/0.05% Brij for a total of five washes. Subsequent incubations were
performed at room temperature with material diluted in 0 .1 M PBSB, with intervening
washes performed as above. Finally, after an incubation with alkaline phosphatase-
conjugated goat anti-rabbit IgG antisera (Sigma Chemical Co.) at 1 :500 in PBSB for 1 h,
the plates were washed, and developer containing 1 mg/ml of nitrophenyl phosphate
(Sigma Chemical Co.) in 10 ml of diethanolamine buffer (97 ml diethanolamine, 1 ml 1
M MgC12, 1 ml 0.1 M zinc acetate, 0.2 gm sodium azide, and 800 ml distilled water, pH
9 .8) was added. The plates were incubated at 37°C, and after 1 h, were read at 405 nm
in an automated ELISA reader (Titertek Multiscan; Flow Laboratories, McLean, VA).
Results
Immunologic Studies ofStreptococcal Hyaluronate Using the Precipitin Reaction and
OtherMethods. Sera from the four rabbits were tested, during the course of the
immunization, for the presence of precipitating antibodies. We used both the
capillary method and the Ouchterlony method. No precipitating antibodies were
detected over a range of concentrations of the streptococcal hyaluronate prepa-
rations. In preliminary experiments, microagglutination reactions were at-
tempted using formalinized group C streptococci. Streptococci were diluted in
PBS to form a dilute suspension in 96-well microtiter plates (Costar, Cambridge,
MA). The results were read using an inverted microscope (Carl Zeiss, Thorn-
wood, NY). Some agglutination was seen with immune sera from rabbit 4512 at
titers of <1 :40 . In an attempt to show that such agglutination was due to specific
reactions with the hyaluronate capsule, inhibition experiments were performed
in which the sera were preincubated with IA or IAI (up to 100 lAg/ml) for 2 h at
room temperature, and overnight at 4 ° C before agglutination tests. However,
no reproducible inhibition of agglutination could be detected.
Immunologic Studies of BSA-conjugated Hyaluronic Acid.
￿
Rabbit preimmune
sera and sera from the fourth bleeding after immunization were chosen for
testing by ELISA. Results showed that all four rabbits had a significant increase
in the titer of reactivity to hyaluronate-BSA after immunization. Table I sum-
marizes these results. In general, a greater than four-fold rise in titer was noted
in the reactivity to hyaluronate-BSA after the fourth immunization series. Similar
experiments using BSA (Sigma Chemical Co.) as antigen for the ELISA showed
that all sera tested had a reciprocal titer of <20 to BSA, except for rabbit 4514,766 RABBITS IMMUNIZED WITH ENCAPSULATED STREPTOCOCCI
TABLE I
Immune sera were taken from rabbits after the fourth immunization
series. A titer is definedas thedilution ofserumat whichan optical density
(at 405 nm) of LO is obtained after I h of development. Results are
expressed as reciprocal titer.
No Inhibitor
----- -----
4514 peak (1100)
Fic;URE 1.
￿
ELISA studies using hyaluronate-BSA (10 Ag/ml) as antigenandimmune rabbit
serum (4514, fourth bleeding) at a 0100 dilution. The broken line represents the results of
the serum incubated alone without inhibitor. The inhibitors were used at varying dilutions,
and were preincubated with the rabbit serum for 4 h at room temperature and overnight at
VC before assay. Final concentrations arepresented for all data, (HeS, heparan sulfate; Chs,
chondroitin-4-sulfate;1A, fraction IA; HuHya, human hyaluronate from umbilical cord; BSA,
bovine serum albumin).
which had a titer of<40. These results indicated that the reactivity to hyaluro-
nate-BSA observed was not due to reactivity to BSA.
To further confirm that the reactivity ofthe rabbit sera was directed against
hyaluronate, inhibition experiments were performed. For these experiments,
sera were preincubated with inhibitors at room temperature with rotation for 2
h and then overnight at VC. In 11g, 1, the results ofa representative inhibition
of rabbit 4514 (1:100) was prein-
ELISA StudiesofPreimmune
Hyaluronate-BSA and
andPeak Immune Rabbit Sera to
to Biotinylated Hyaluronate
Rabbit number Preimmune titer
Hyaluronate-BSA
4511 <100 400
4512 <50 400
4513 <400 1,600
4514 WO 800
Biotinylated Hyaluronate
4511 <100 12,800
4512 <100 3,200
4513 <100 25,600
4514 <100 12,8002.0[-
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FIGURE 2.
￿
ELISA studies of hyaluronate-BSA usinga rabbit antiserum to BSA. The studies
were performed and are presented as in Fig. 1.
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￿
ELISAstudies usingbiotinylated IA, (IA,-B) (10 ug/ml) as antigen. Allbleedings
of each rabbit (4511, 4512, 4513, and 4514) before and during immunization with encaplsu-
latedstreptococci were tested at a final concentration of 1 :200.
cubated with fraction IA, human hyaluronate, heparan sulfate, chondroitin
sulfate, and BSA in varying concentrations. As can be seen from the figure,
fraction IA (streptococcal hyaluronate) and human hyaluronate inhibited the
reactivity of sera 4514 (bleeding four) to hyaluronate-BSA in a dose dependent
manner, while BSA inhibited the reactivity to hyaluronate-BSA only in the
largest dose (250 ug/ml). No effect was seen when heparan sulfate or chondroitin
sulfate were used as inhibitors . 'Since these glycosaminoglycans both contain
hexosamine and uronic acid and are highly anionic, similar to hyaluronate, this
result confirms the specificity of the inhibition reaction to the hyaluronate
polysaccharide. To eliminate further the possibility that hyaluronate might have
some nonspecific effect in the inhibition reaction, the reactivity of a rabbit
antiserum to BSA (Cappel Laboratories) was tested in the ELISA using hyalu-
ronate-BSA. This antiserum was preincubated with either fraction 1A, human
hyaluronate, or BSA. Only BSA significantly inhibited the reactivity of the rabbit
anti-BSA serum with hyaluronate-BSA in a dose-dependent manner (Fig. 2) .
Immunologic Studies of Biotinylated Hyaluronic Acid.
￿
Streptavidin was coated
in ELISA plates at 10 jig/ml in Tris buffer at room temperature for 4 h. After
washing, IAI-B in PBSB was added and incubated for 2 h at room temperature,
and then overnight at 4°C. After washing the plates, rabbit sera were added at76 8
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FIGURE 4.
￿
ELISA studies employing IA I-B as antigen . The plates were preincubated with
biotin (I mg/ml, biotin/PBSB) before the addition of IA I-B to specifically block the attachment
of IA I-B. Peak immune rabbit serum was then added in varying dilutions . In control wells,
only PBSB and no biotin was added .
varying dilutions in PBSB for 1 h . Subsequent steps were performed as described
above .
Fig . 3 shows the results of a study in which each bleeding from each rabbit
was studied at a final dilution of 1 :200 . All four rabbits clearly developed
increased reactivity to the IA I -B during the immunization period . Rabbits 4513
and 4514, which were immunized with group C D181 streptococci containing
more extensive capsules, developed generally higher titers earlier during the
course of immunization than rabbits 4511 and 4512, which were immunized
with group A S23op streptococci possessing less abundant capsules . In titration
experiments comparing the titer of preimmune sera with those obtained after
the fourth immunization, a >32-256-fold increase in titer was noted (Table I) .
The observation that the IA I-B is a much better antigen in the ELISA than the
hyaluronate-BSA may be related, in part, to the fact that long-chain hyaluronate
was used for conjugation with BSA, while hyaluronidase-digested hyaluronate
was used for conjugation with biotin .
To show that the sera were indeed specifically reacting with the biotinylated
hyaluronate, the following experiment was performed . After coating the plates
with streptavidin and washing, the plates were incubated with either PBSB alone
or biotin (I mg/ml) in PBSB, for I h . The plates were washed, IA I -B was added,
followed by the addition of sera (1 :1000) and other reagents according to the
protocol above . In this way, the free biotin should prevent the binding of the
biotinylated hyaluronate . As shown in Fig . 4, this was indeed the case . The plate
was read at 2 h to accentuate the differences . While the preimmune sera showed
only background activity, the immune sera reacted with a titer of >12,800 .
However, the addition of free biotin abolished this reactivity almost completely,
indicating that the sera were indeed reacting with the biotinylated hyaluronate .
Similar results were noted with all four rabbit sera .
To confirm that the ELISA reliably measures antipolysaccharide antibody,
2.0
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FIGURE 5.
￿
ELISA studiesemployingIA,-B as antigen. Variousinhibitors were preincubated
with peak immune rabbit serum as described in Fig. 1. Abbreviations as in Fig. 1, plus PS,
type III pneumococcal polysaccharide;Hep, heparin.
group C meningococcal polysaccharide prepared according to methods previ-
ously described (24) was biotinylated in the same manner as described above for
the hyaluronate. Human and rabbit sera shown (26) to contain antibody to the
group C meningococcal polysaccharide by a passive hemagglutination method
were used for testing. Results in the ELISA were identical to those found with
RIA. Titers of group C meningococcal antibody in immune rabbit sera were
found to be >2 .5 x 106 (reciprocal titer). Biotin inhibition experiments similar
to those described above completely eliminated the rabbit sera reactivity.
The specificity of the immune rabbit sera were investigated by inhibition
experiments. These were performed as described above, by preincubating the
sera with inhibitors overnight before assay. These experiments showed that the
reactivity of all four rabbit sera was directed against hyaluronic acid (represent-
ative data shown in Fig. 5). Only preparations of hyaluronate were effective as
inhibitors, including both mammalian and streptococcal hyaluronate. Inhibition
of reactivity was shown using fraction IA2, which was the most purified prepa-
ration of hyaluronate available, containing 50% glucuronic acid and 50% N-
acetylglucosamine. This result made it highly unlikely that contaminating sub-
stances accounted for such reactivity, particularly since 50% inhibition of reac-
tivity was noted with 1 /ig/ml of IA2. Further, the same hypothetical contaminant
would need to be present both in the streptococcal and the mammalian hyalu-
ronate preparations, a situation that seems highly unlikely.
The specificity of the epitope that accounted for the observed immunoreactiv-
ity was studied by specific inhibition experiments (Fig. 5). Other charged poly-
saccharides containing uromc acid, including the type III pneumococcal polysac-
charide and glycosaminoglycans (including heparan sulfate, heparin, chondroitin
sulfate) were completely ineffective inhibitors. This result indicated, as wasshown
previously, that the immunoreactivity was directed against specific epitopes of
the hyaluronate polysaccharide.
The results of these experiments also showed that while intact, long chain
hyaluronate was a relatively poor inhibitor of the serum reactivity to IA I-B,
hyaluronidase-digested preparations of streptococcal hyaluronate were -100-
fold more effective as inhibitors (Fig. 5). To confirm this hypothesis, 2 mg of
mammalian hyaluronate (from human umbilical cord; Miles Laboratories), at a
concentation of 1 mg/ml in 0.15 M NaCI, pH 6, was digested with 0.2 ml770
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FIGURE 6.
￿
ELISA studies using IArB as antigen. Inhibitors were preinwbaed with peak
immune rabbit serum. hWHYA digest, human hyaluronate digested with hyaluronidase.
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FIGURE 7.
￿
ELISA studies using IA,-B as antigen. Peak immune rabbit serum was preincu-
bated with various monosaccharides.
testicular hyaluroniclase (I mg/ml in 0. 15 M NaCl, pH 6, 400 U/mg; Worthing-
ton Biochemical Corp.) and rotated for 4 h at room temperature. The material
was centrifuged and the supernatant was precipitated three times with absolute
ethanol. Finally, the precipitate was washed in ether and dried in air. The
partially digested mammalian hyaluronate was approximately five times more
effective as an inhibitor than the original startingpreparation (Fig. 6). This result
suggested that a determinant of the hyaluronate that was partially exposed on
the long chain was further exposed after hyaluroniclase treatment. Since hyalu-
ronate is a repeating disaccharide, either of the monosaccharides, N-acetylglu-
cosamine or glucuronic a64 could be theprimary immunodeterminant ofserum
reactivity. Inhibition reactions performed using these monosaccharides showe
that gkc"o&c add {sodium salt} was an effective inhibitor of serum reach
to IAI-B, while N-acetylglucosamine and N-acetylgalactosamine were ineffective
inhibitors (Fig. 7). Galacturonic acid was also an effective inhibitor of serum
reactivity, though generally somewhat less so. All monosaccharide solutions had
a pH of 7.2. These results indicated that a terminal glucuronic acid unit is
probably the primary epitope of the major immunodeterminant responsible for
the immune response to hyaluronic acid in these sera, and that this epitope was
shared by galacturonic acid.
To investigate further the hypothesis that an epitope on a terminal monosac-
charide of the polysaccharide chain was responsible for the serum reactivity toO
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FIGURE 8. ELISA studies employing IA,-B as antigen. Peak immune rabbit serum was
preincubated with various inhibitors. IA,, periodate, IA, treated with periodate; IA,, carbodi-
imide, IA, treated with carbodiimide.
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FIGURE 9.
￿
ELISA studies using IA,-B as antigen. Peak immune rabbit serum was preincu-
bated with various monosaccharides.
IAI-B, the IA, was treated with periodate and borohydride, as described in
Materials and Methods, to preferentially destroy the terminal monosaccharide
of the polysaccharide chain. As seen in Fig. 8, these results show that periodate
oxidation and borohydride reduction effectively reduced the antigenicity of the
IA, polysaccharide.
Finally, we investigated the hypothesis that the determinant shared by glucu-
ronic acid and galacturonic acid which was the immunodominant site of serum
reactivity to hyaluronate was the carboxyl group of the terminal glucuronic acid.
IAI was treated with carbodiimide and then subjected to borohydride reduction,
destroyingthe carboxyl group. This procedure significantly reducedthe antigen-
icity of the IAI polysaccharide (Fig. 8). This was also shown using glucose and
glucuronamide as inhibitors. The differences among these hexoses are illustrated
in Fig. 9. As seen in Fig. 9, only glucuronic and galacturonic acid were effective
inhibitors of serum reactivity. In summary, these data provide evidence that the772
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carboxyl group of the terminal glucuronic acid of hyaluronate is the primary
focus of the immune response to hyaluronic acid in rabbits immunized with
encapsulated streptococci .
Discussion
This study reveals the presence of antibodies to hyaluronate in the sera of
rabbits immunized with formalinized, encapsulated group A and group C strep-
tococci . These same sera were tested earlier for precipitating antibodies, and
none were found. One possible explanation for the discrepancy is that the
concentration of specific antibody is too low to yield visible precipitates, and that
positive reactions can only be detected with tests ofmuch higher sensitivity, such
as the ELISA . However, a second possibility is raised by the inhibition experi-
ments, which suggest that theantibodies recognize only the terminal nonreducing
residues of the hyaluronate molecule . Since the hyaluronate is an unbranched,
linear molecule, antibodies of this type could not build a precipitating lattice. An
analogy to this situation has been described by Braun (27) in relation to the
antibody response to the cell wall carbohydrate of group A and A variant
streptococci . 90% of the antibodies mice produced against these antigens rec-
ognize only the terminal nonreducing end of the molecule (N-acetylglucosamine
and rhamnose, respectively), and are thus nonprecipitating . Braun has confirmed
this with the isolation of mAbs to the carbohydrate, 90% of which are of the
nonprecipitating type .
The results of the experiments reported here indicate that the terminal
glucuronate of the hyaluronate molecule is the dominant determinant of speci-
ficity, with the carboxyl group playing a significant role . This is supported by
the inhibitory effect of sodium glucuronate (and to a somewhat lesser extent,
sodium galacturonate) and the lack of inhibition by N-acetylglucosamine . The
fact that increasing the concentration of terminal glucuronide residues by partial
enzymatic hydrolysis markedly enhanced the inhibitory effect of hyaluronate
preparations is consistent with the possibility that the antibodies are only recog-
nizing the nonreducing terminus of the hyaluronate molecule . When IA I was
treated with periodate oxidation and borohydride reduction, preferentially de-
stroying the terminal glucuronide (since there are no other cis-hydroxyl groups
in the polysaccharide), the antigenicity of IA I was destroyed, providing more
evidence that a terminal glucuronide is the primary immunodeterminant of
hylauronate . The specificity of the reaction for the carboxyl group of the
glucuronide was revealed by the demonstration that galacturonic acid was also
an effective inhibitor ofserum reactivity, while glucose and glucuronamide had
minimal inhibitory effect . Finally, elimination of the carboxyl groups of IA I by
reduction with carbodiimide followed by borohydride reduction eliminated the
antigenicity of the IA I , further demonstrating that the immunodominant site of
antibody reactivity to hyaluronate is the carboxyl group of the terminal glucu-
ronide . Kozel and Gotschlich (28) have previously shown that rabbits can form
carboxyl-specific antibody against polysaccharides containing uronic acid . Al-
though the antibodies produced in response to immunization with hyaluronate
are directed against a carboxyl group of glucuronate as the primary immunode-
terrninant, the lack of inhibition by other polysaccharides also containing glucu-FILLIT ET AL.
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ronate (such as other glycosaminoglycans and the pneumococcal polysaccharide)
indicates that this epitope is only part of the complete antigenic determinant of
the hyaluronate polysaccharide.
Previous attempts to identify antibodies to hyaluronate have been unsuccessful
despite the use of a variety of methods for immunization and detection of
antibody (2-11). Although Lowenthal (7) suggested that antibodies may be
induced to hyaluronate by using young cultures that are carefully heat killed,
this work has been subsequently criticized (11) because of the possibility that
contaminants from culture broth might have been responsible for the presence
of precipitins in immune sera. Sandson et al. (10) also suggested that antibodies
to hyaluronate could be induced in rabbits by immunization with connective
tissue components. However, the presence of protein and galactosamine in their
preparations of hyaluronate suggests the presence of components other than
hyaluronate that might account for the observed immunoreactivity of their
immune sera . Recent studies using more sensitive techniques have shown the
presence of antibodies reacting with hyaluronate in the seurm of various species
(12) including humans (13).
Although polysaccharides vary greatly in their immunogenicity, hyaluronate
appears to be a poor immunogen. Among polysaccharides containing uronic
acid, some polysaccharides are highly immunogenic, such as the pneumococcal
polysaccharides (29) and cryptococcal polysaccharides (28) . The apparent poor
immunogenicity of streptococcal hyaluronate has been attributed to the fact that
hyaluronate is a normal constituent of many mammalian tissues, and therefore
normal suppressive immune mechanisms prevent the recognition of a hyaluro-
nate immunogen as foreign. However, many common host components may be
the focus of an immune response, including other glycosaminoglycans (30-32).
An alternate possibility to explain the apparent lack of immunogenicity of
hyaluronate is that naturally occurring antibodies to native host molecules may
occur, but may be difficult to detect because of their absorption by excess host
antigens (33).
The biologic significance of immune reactions to hyaluronate in the pathogen-
esis of streptococcal infections and autoimmune disease is not known. It is
conceivable that immune reactions to hyaluronate could contribute to host
defenses against streptococcal infections. The induction of autoimmunity to
mammalian hyaluronate by streptococcal infections with encapsulated organisms
could be a mechanism for the induction of autoimmunity to tissue hyaluronate
in man. We have shown that a number of extracellular matrix components,
including proteoglycan, laminin, and type IV collagen may be the focus of an
immune response in humans (14, 34, 35). However, further investigation is
required before these experimental results can be related to the pathogenesis of
human disease.
Summary
The immunogenicity of hyaluronic acid was investigated. Rabbits were im-
munized with encapsulated group A and C streptococci . Intact long-chain hya-
luronate was conjugated to BSA for use as antigen in an ELISA. Antibodies to
the hyaluronate-BSA conjugate were detected in peak immune sera. The speci-774
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ficity of the antibodies for both mammalian and streptococcal hyaluronate was
shown by inhibition studies. To further confirm the presence of antihyaluronate
antibodies, hyaluronidase-digested streptococcal hyaluronate was conjugated to
biotin and used as an antigen in the ELISA. A clear immunization effect was
shown for each rabbit by the study of preimmune and postimmunization bleed-
ings. Titers for each rabbit increased by >32-256-fold. Inhibition studies using
hyaluronidase-digested hyaluronate and periodate-treated hyaluronate showed
that the immunodominant site of antibody reactivity was a terminal glucuronic
acid residue . Further studies showed that the carboxyl group of the terminal
glucuronide was the major immunoreactive site. Both mammalian and strepto-
coccal hyaluronate inhibited the immune rabbit sera reaction to streptococcal
hyaluronate, demonstrating crossreactivity of these molecules. Thus, hyaluronate
was shown to be immunogenic in rabbits.
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